Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review

Frontiers in Pharmacology

Pharmacology

Annabelle Huang¹  Wei-Qi Wei¹  Monika E. Grabowska¹  Bingshan Li²  Zhexing Wen³ 

[1] Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, United States;Department of Molecular Physiology and Biophysics, Vanderbilt University Medical Center, Nashville, TN, United States;Departments of Psychiatry and Behavioral Sciences, Cell Biology, and Neurology, Emory University School of Medicine, Atlanta, GA, United States;

关键词: Alzheimer’s disease;    drug repurposing;    validation;    real-world data;    electronic health records;   

DOI  :  10.3389/fphar.2023.1257700

 received in 2023-07-13, accepted in 2023-08-28,  发布年份 2023

来源: Frontiers

【 摘 要 】

Background: Alzheimer’s disease (AD) is a debilitating neurodegenerative condition with few treatment options available. Drug repurposing studies have sought to identify existing drugs that could be repositioned to treat AD; however, the effectiveness of drug repurposing for AD remains unclear. This review systematically analyzes the progress made in drug repurposing for AD throughout the last decade, summarizing the suggested drug candidates and analyzing changes in the repurposing strategies used over time. We also examine the different types of data that have been leveraged to validate suggested drug repurposing candidates for AD, which to our knowledge has not been previous investigated, although this information may be especially useful in appraising the potential of suggested drug repurposing candidates. We ultimately hope to gain insight into the suggested drugs representing the most promising repurposing candidates for AD.Methods: We queried the PubMed database for AD drug repurposing studies published between 2012 and 2022. 124 articles were reviewed. We used RxNorm to standardize drug names across the reviewed studies, map drugs to their constituent ingredients, and identify prescribable drugs. We used the Anatomical Therapeutic Chemical (ATC) Classification System to group drugs.Results: 573 unique drugs were proposed for repurposing in AD over the last 10 years. These suggested repurposing candidates included drugs acting on the nervous system (17%), antineoplastic and immunomodulating agents (16%), and drugs acting on the cardiovascular system (12%). Clozapine, a second-generation antipsychotic medication, was the most frequently suggested repurposing candidate (N = 6). 61% (76/124) of the reviewed studies performed a validation, yet only 4% (5/124) used real-world data for validation.Conclusion: A large number of potential drug repurposing candidates for AD has accumulated over the last decade. However, among these drugs, no single drug has emerged as the top candidate, making it difficult to establish research priorities. Validation of drug repurposing hypotheses is inconsistently performed, and real-world data has been critically underutilized for validation. Given the urgent need for new AD therapies, the utility of real-world data in accelerating identification of high-priority candidates for AD repurposing warrants further investigation.

【 授权许可】

Unknown   
Copyright © 2023 Grabowska, Huang, Wen, Li and Wei.